Lipid Particle CAR Gene Transfer for Efficient CAR-T Cell Expansion

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing methods for proliferating CAR-T cells are not sufficiently efficient, leading to high production costs and suboptimal therapeutic effects.

Innovation Solution

A method involving the use of lipid particles containing a CAR antigen gene, which are brought into contact with CD209 positive cells to transfer the gene and produce CAR antigen-expressing cells, followed by co-culturing with CAR-T cells to enhance proliferation.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If conventional proliferation methods are used, then production cost is reduced, but proliferation efficiency is insufficient

Engineering Contradiction:

Improveproliferation efficiencyVSAvoidproduction cost

Core Design Contradiction:

ProductivityVSEase of manufacture

Solution Approach 1:

The patent introduces CD209 positive cells as intermediary antigen-presenting cells that express CAR antigens. These intermediary cells enable efficient CAR-T cell proliferation through co-culture, resolving the contradiction by providing a cost-effective intermediary system that achieves high proliferation efficiency without requiring complex or expensive conventional stimulation methods

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent changes the parameter of antigen presentation by using CD209 positive cells that naturally express CAR antigens. This parameter change enables efficient CAR-T cell proliferation through co-culture, achieving high productivity while maintaining ease of manufacture by utilizing naturally occurring cell properties rather than complex artificial stimulation systems

Inventive Principle:

Principle #35Parameter changes

2Reliability

If conventional stimulation steps are used, then therapeutic effect is maintained, but production cost increases

Engineering Contradiction:

Improvetherapeutic effectVSAvoidproduction cost

Core Design Contradiction:

ReliabilityVSEase of manufacture

Solution Approach 1:

The patent employs CD209 positive cells as intermediary antigen-presenting cells that maintain therapeutic effect through natural CAR antigen expression. This intermediary approach ensures reliable therapeutic outcomes while reducing production costs by avoiding complex conventional stimulation protocols

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The CD209 positive cells naturally express CAR antigens without requiring external stimulation or complex manufacturing processes. This self-service property of the cells enables them to maintain therapeutic effect while simplifying the production process and reducing costs

Inventive Principle:

Principle #25Self-service

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach significantly enhances the efficiency of CAR-T cell proliferation, reducing production costs and improving therapeutic efficacy.

Implementation Method 1

producing a CAR antigen-presenting cell by bringing the lipid particle into contact with the CD209 positive cell and transfecting the nucleic acid into the CD209 positive cell

Methodology Applied

Scientific EffectLipid particle membrane fusion:

Data Source

PatentUS20260062717A1Method for proliferating car-t cells, and lipid particles and kit for use in the method

Publication Date: 2026.03.05 KK TOSHIBA

AI summary

According to one embodiment, a lipid particle for producing a CAR antigen-expressing cell derived from a CD209 positive cell is provided. The lipid particle includes a lipid membrane having a lumen, and a nucleic acid containing a CAR antigen gene being contained in the lumen.